Successful Drug Discovery, Volume 5. Группа авторов
of Health in the EU Cycle, vol. 2020. Paris/Brussels: OECD Publishing/European Union.
124 124 NIH (2018). NIH Central Resource for Grants and Funding Information - Peer review, Vol. 2020, https://grants.nih.gov/grants/peer-review.htm (accessed 18 May 2020).
Biography
Oliver Plettenburg studied chemistry at the University of Wuppertal and obtained his PhD under the supervision of Prof. Hans‐Josef Altenbach in 2000. He then moved to The Scripps Research Institute, La Jolla, to work under the guidance of Prof. Chi‐Huey Wong, where he focused on the synthesis of glycolipids. After this he joined the pharmaceutical industry at Aventis Pharma, working first in classical medicinal chemistry and developing projects from hit and lead optimization phase all the way to early clinical trials. Later he was more and more involved in establishing alternative concepts in pharmaceutical research, and lastly he held positions as “Head of Chemical Biology” and “Head of Biosensors and Chemical Probes” at Sanofi‐Aventis, Frankfurt, Germany. From 2016, Dr. Plettenburg serves as founding director of the Institute of Medicinal Chemistry of the Helmholtz Center Munich, and he is also a full professor for Medicinal Chemistry at Leibniz Universität Hannover. His research focuses on hit and lead optimization to open up new treatment options for severe diseases like diabetes, lung, inflammatory, or infectious diseases. Furthermore, he develops innovative targeted and smart drug delivery methods and works on the synthesis of novel imaging agents for in vivo monitoring of pathogenesis.
Конец ознакомительного фрагмента.
Текст предоставлен ООО «ЛитРес».
Прочитайте эту книгу целиком, купив полную легальную версию на ЛитРес.
Безопасно оплатить книгу можно банковской картой Visa, MasterCard, Maestro, со счета мобильного телефона, с платежного терминала, в салоне МТС или Связной, через PayPal, WebMoney, Яндекс.Деньги, QIWI Кошелек, бонусными картами или другим удобным Вам способом.